GlassScriptPhysician profile
Lacy C Thomas
NPI 1427615087
$3,036.05
in general payments reported to CMS, 2019-2025
31 companies · $694 in 2025
The $694 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $406 · 2022: $559 · 2023: $574 · 2024: $803 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $608.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $403.20 | 2022-2025 | |
| Glaxosmithkline, LLC. | $395.65 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Supernus Pharmaceuticals, INC. | $246.83 | 2024 | Qelbree |
| Lilly USA, LLC | $192.81 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $163.58 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $120.69 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $115.13 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $87.54 | 2021-2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $68.12 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.08 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.73 | 2021-2022 | |
| Astellas Pharma US INC | $64.38 | 2022-2024 | Myrbetriq, Veozah |
| Amgen INC. | $51.33 | 2021-2023 | Repatha |
| Merck Sharp & Dohme LLC | $51.24 | 2023 | Dificid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $43.16 | 2023-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $39.67 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $39.20 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $28.72 | 2023-2024 | Nuedexta, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $21.16 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $20.91 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.52 | 2022 | |
| Corium, LLC | $17.47 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $16.02 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.96 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.87 | 2024 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.57 | 2024 | Xifaxan, Trulance |
| Seqirus USA INC | $12.69 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Biohaven Pharmaceuticals, INC. | $12.27 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.12 | 2022 | |
| Genentech USA, INC. | $7.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacy Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.